February 21, 2024
Plasma Protease C1-inhibitor Treatment Market

Plasma Protease C1-inhibitor Treatment Market driven by Rising Prevalence of Angioedema Disorders

Plasma protease C1-inhibitor treatment is a type of plasma-derived protease inhibitor that is used to treat hereditary angioedema (HAE), a rare genetic condition characterized by recurrent episodes of swelling (edema) affecting various superficial tissues of the body such as the hands, feet, face, gastrointestinal tract and airway. This treatment helps to inhibit C1-esterase, a key enzyme involved in the complement system and therefore preventing uncontrolled cleavage and activation of other complement components and generation of inflammatory peptides that cause angioedema attacks. Rising prevalence of HAE and other angioedema disorders globally is driving the demand for targeted plasma protease C1-inhibitor treatment options for quick symptom relief and management of life-threatening airway swelling attacks associated with this condition.

The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the plasma protease C1-inhibitor treatment market is the focus on developing subcutaneous and oral drug formulations to replace the standard intravenous route of administration. Intravenous administration requires frequent hospital visits for plasma-derived C1-inhibitor replacement therapy which can be inconvenient for many patients. Oral and subcutaneous formulations are being studied currently to enable self-administration at home and improve treatment convenience. Ongoing clinical research in combination with novel drug delivery technologies holds potential to transform the plasma protease C1-inhibitor treatment landscape over the forecast period.

Porter’s Analysis

Threat of new entrants: Low barrier for new companies to enter the market given established distribution channels and manufacturing expertise required.

Bargaining power of buyers: Large customer base of hospitals and research labs gives buyers higher negotiating power over pricing.

Bargaining power of suppliers: Few manufacturers globally able to produce plasma protease C1-inhibitor for treatment, giving them stronger influence over pricing and supply.

Threat of new substitutes: Limited alternatives currently available for plasma protease C1-inhibitor treatment though research ongoing into new drug therapies.

Competitive rivalry: Intense competition among existing players to gain greater market share through new product launches and geographic expansion.

Key Takeaways

The Global Plasma Protease C1-inhibitor Treatment Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.

North America currently dominates the market owing to established healthcare infrastructure and large patient population. The region is expected to maintain its leading position during this period. Europe is also a major market for plasma protease C1-inhibitor treatment supported by favourable reimbursement policies. The Asia Pacific region is anticipated to grow at the fastest pace due to rising medical tourism, healthcare spending and increasing awareness about treatment options.

Key players related content comprises- Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. Currently Philips and Panasonic hold largest shares of the market. New product approvals and partnerships for expanding geographic presence are key strategies adopted by these companies.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it